The pharmaceutical industry runs on two paths - generics and frontier innovation. Between them lies the middle lane.

RT001, Revio’s repurposed therapy for Duchenne Muscular Dystrophy, has been granted FDA Orphan Drug Designation, advancing its path toward clinical evaluation.

Nanoform and Revio Therapeutics partner to develop GLIORA, a long-acting hydrogel combining olaparib and temozolomide for improved glioma treatment.

Revio Therapeutics, a privately held specialty pharma start-up focused on repurposing & optimizing approved medicines...